- New Equilibrium Biosciences, Mass.-based company that advances a rational drug design against intrinsically disordered proteins (IDPs), closed a $10m in seed funding
- RA Capital Management made the investment
- The company intends to use the funds to scale up R&D facility, expand the team, and accelerate programs targeting IDPs while exploring strategic partnerships
- New Equilibrium also provides a platform that reveals opportunities for structure-based design by learning biophysics with AI
- NEQ’s platform combines AI and biophysics to reveal experimentally-invisible conformations of shapeshifting proteins
- This technology enables the rational design of drugs targeting the elusive class of intrinsically disordered proteins
